Cannovex

Agoralaan Building Abis /
3590 Diepenbeek
BE
Cannovex
Foundation date
06/08/2016
Sector
#Biotechnology - otherSubsector
Therapeutic areas
- #Digestive system
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the eye
- #Diseases of the nervous system
- #Endocrine - nutritional and metabolic diseases
- #Mental and behavioural disorders
- #Musculoskeletal system and connective tissue
- #Neoplasms / cancer / oncology
- #Respiratory system
- #Skin and subcutaneous tissue
Cannovex is a Benelux-origin biotech company which develops cannabinoid-based medicines to improve the lives of patients worldwide. Over a two year period, Cannovex has conducted an in-depth and exhaustive study of medical literature on this subject, and continues to monitor all scientific publications. These efforts establish Cannovex as the designated conversation partner, sounding board and source of information on cannabinoid medicines for all stakeholders.
Based on the insights resulting from the above-mentioned research, Cannovex is now planning the development of cannabinoid-based medicines in specific therapeutic areas and for well-defined indications. Cannovex aims to set up clinical studies, in collaboration with EU university hospitals, to provide proofs of concept (PoC). Based on these PoCs, Cannovex will explore partnerships with pharmaceutical companies to conduct end-stage clinical trials, to apply for market authorisation with European Medicines Agency (EMA) and similar authorities, and to bring our cannabinoid medicinal products to the markets worldwide.
Upcoming events
All events-
2809 '22
NLSDays 2022
Event by: SwedenBIO -
2809 '22
Neurotechnologies
Event by: VIB -
0712 '22
Emerging Applications of Microbes (2nd edition)
Event by: VIB
Latest news
More news-
Mayne Pharma and Mithra announce FDA approval of HALOETTE®, a generic version of NUVARING®
Monday August 8th 2022
Read more
-
S-Biomedic welcomes Pascal Yvon to lead its B2B commercial activities
Tuesday August 2nd 2022
Read more
-
Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial
Monday August 1st 2022
Read more
Jobs
More jobs-
10/08/22
Flemish Brabant
Laboratory Technicians in Angiogenesis and Vascular Metabolism
Permanent
VIB -
10/08/22
Flemish Brabant
Postdoctoral researcher “Microfluidic single cell sorting of circulating tumor cells”
Permanent
VIB -